Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd

MARLBOROUGH, Mass., June 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today declared that it has entered into a definitive settlement with Synergy Innovation Co., Ltd, to purchase its majority stake (close to 64 %) of M.I.Tech Co., Ltd, (“M.I.Tech”) a publicly traded Korean producer and distributor of healthcare equipment for endoscopic and urologic treatments. M.I.Tech is the creator of the HANAROSTENT technologies, a household of conformable, non-vascular, self-growing metal stents, which have been distributed by Boston Scientific in Japan since 2015. The agreement is composed of a buy price tag of KRW 14,500 per share, which signifies a total of KRW 291.2 billion or somewhere around $230 million at present-day exchange prices, subject matter to closing adjustments.

Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation)

Non-vascular gastrointestinal and airway stents are applied to assist clear occlusions or strictures in various regions of a patient’s anatomy, which includes the biliary tree, pancreatic duct, esophagus, colon and duodenum. In many conditions, stent placement is minimally invasive and may perhaps help speedier patient restoration as opposed to surgical procedure.1,2 The HANAROSTENT technological know-how functions a special hook-cross nitinol design and style intended to supply a pure and versatile fit in a patient’s anatomy, as very well as flared ends to enable prevent stent migration.

“M.I.Tech is an innovator in non-vascular stent enhancement, with products choices that enhance our present stent portfolio, together with the differentiated AXIOS™ Stent and Electrocautery Improved Shipping and delivery Method and the flexible and conformable Agile™ Esophageal Stent Process,” said Artwork Butcher, govt vice president and group president, MedSurg and Asia Pacific, Boston Scientific. “We are committed to investing in systems that progress treatment for patients close to the earth and are keen to function extra closely with M.I.Tech to broaden their worldwide footprint.”

The firm expects to finish the transaction in the second fifty percent of 2022, matter to customary closing disorders. The affect to GAAP and altered earnings per share is envisioned to be immaterial in 2022.

About Boston Scientific 
Boston Scientific transforms life via progressive healthcare answers that enhance the well being of patients around the entire world. As a world-wide health-related engineering chief for additional than 40 years, we progress science for lifestyle by delivering a broad assortment of substantial overall performance alternatives that handle unmet individual desires and decrease the charge of health care. For far more information and facts, visit and join on Twitter and Facebook.

Cautionary Statement With regards to Forward-Hunting Statements 
This press launch includes forward-seeking statements inside of the this means of Area 27A of the Securities Act of 1933 and Section 21E of the Securities Trade Act of 1934. Ahead-searching statements may be discovered by words and phrases like “foresee,” “count on,” “task,” “imagine,” “approach,” “estimate,” “intend” and equivalent phrases. These ahead-seeking statements are based mostly on our beliefs, assumptions and estimates applying data available to us at the time and are not intended to be ensures of potential functions or functionality. These ahead-looking statements involve, among other issues, statements with regards to the money and company impression of the transaction, merchandise launches and products overall performance and affect. If our fundamental assumptions flip out to be incorrect, or if particular threats or uncertainties materialize, precise effects could change materially from the expectations and projections expressed or implied by our ahead-hunting statements. These aspects, in some circumstances, have affected and in the potential (with each other with other aspects) could influence our ability to implement our organization system and may well induce precise final results to differ materially from individuals contemplated by the statements expressed in this press release. As a end result, audience are cautioned not to spot undue reliance on any of our forward-on the lookout statements.

Aspects that may trigger these types of dissimilarities include things like, amongst other things: long run financial, aggressive, reimbursement and regulatory conditions new merchandise introductions demographic developments the closing and integration of acquisitions mental home litigation economic market ailments and upcoming business conclusions made by us and our rivals. All of these elements are challenging or not possible to predict precisely and numerous of them are further than our command. For a further more listing and description of these and other critical hazards and uncertainties that may impact our long term operations, see Element I, Product 1A – Risk Factors in our most modern Annual Report on Variety 10-K submitted with the Securities and Trade Commission, which we could update in Section II, Item 1A – Possibility Factors in Quarterly Reports on Sort 10-Q we have submitted or will file hereafter. We disclaim any intention or obligation to publicly update or revise any ahead-looking statements to reflect any modify in our anticipations or in gatherings, situations or circumstances on which those people anticipations might be centered, or that may possibly have an affect on the chance that real outcomes will differ from those people contained in the ahead-on the lookout statements. This cautionary statement is relevant to all ahead-hunting statements contained in this document.


Kirsten Lesak-Greenberg 
Media Relations 
(763) 300-9254 
[email protected]

Lauren Tengler 
Trader Relations 
(508) 683-4479 
[email protected]

1 Zhou, W. Z., & Yang, Z. Q. (2014). Stenting for malignant gastric outlet obstruction: Current position. Gastrointestinal Intervention, 3(2), 65–68.
2 Kang S. G. (2010). Gastrointestinal stent update. Intestine and liver4 Suppl 1(Suppl 1), S19–S24.


Cision Perspective primary content material to download multimedia: greater part-stake-of-mitech-co-ltd-from-synergy-innovation-co-ltd-301568467.html

Supply Boston Scientific Corporation